SecBot SecBot
SECBOTREPLAY Home › Report › PULM

PULM · Pulmatrix filed a Rule 425 communication on behalf of Eos SENOLYTIX,…

Pulmatrix, Inc. · 425 filed Jun 5, 2026 at 08:00 ET

At the news

NEUTRALIMPACT 4/10

425 filed Jun 5, 2026 at 08:00 ET

Pulmatrix filed a Rule 425 communication on behalf of Eos SENOLYTIX, announcing preclinical data for PTC-2105 at the Sachs Obesity Forum. The filing reiterates the pending merger with Pulmatrix (expected Q3 2026) and highlights PTC-2105's potential in body composition and survival. No new financial terms or deal changes were disclosed.

  • Eos SENOLYTIX presented preclinical data for PTC-2105 at the Sachs 2nd Annual Obesity & Cardiometabolic Innovation Forum on June 5, 2026.
  • PTC-2105 demonstrated reductions in fat mass greater than GLP-1s, gains in lean mass, and improved physical function in preclinical studies.
  • In naturally aged mice, 40% of the PTC-2105 25 mg/kg cohort remained alive at 146 weeks vs. 100% mortality in controls by 137 weeks (p=0.0142).
  • The merger between Pulmatrix and Eos was announced March 26, 2026, expected to close in Q3 2026, with combined company trading under ticker MTXL.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access